Dataset Information

Abnormalities in nitric oxide and its derivatives in lung cancer.

ABSTRACT:

Rationale

A cellular prooxidant state promotes cells to neoplastic growth, in part because of modification of proteins and their functions. Reactive nitrogen species formed from nitric oxide (NO) or its metabolites, can lead to protein tyrosine nitration, which is elevated in lung cancer.

Objective

To determine the alteration in these NO derivatives and the role they may play in contributing to lung carcinogenesis.

Methods

We analyzed levels of NO, nitrite (NO2-), nitrate (NO3-), and the location of the protein nitration and identified the proteins that are modified.

Measurements and main results

Although exhaled NO and NO2- were increased, endothelial NO synthase or inducible NO synthase expression was similar in the tumor and tumor-free regions. However, immunohistochemistry showed that nitrotyrosine was increased in the tumor relative to non-tumor-bearing sections. We used proteomics to identify the modified proteins (two-dimensional polyacrylamide gel electrophoresis; mass spectrometry). Both the degree of nitration and the protein nitration profile were altered. We identified more than 25 nitrated proteins, including metabolic enzymes, structural proteins, and proteins involved in prevention of oxidative damage. Alterations of the biology of NO metabolites and nitration of proteins may contribute to the mutagenic processes and promote carcinogenesis.

Conclusions

This study provides evidence in favor of a role for reactive nitrogen and oxygen species in lung cancer.

SUBMITTER: Masri FA

PROVIDER: S-EPMC2718532 | biostudies-literature | 2005 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Abnormalities in nitric oxide and its derivatives in lung cancer.

Masri Fares A FA Comhair Suzy A A SA Koeck Thomas T Xu Weiling W Janocha Allison A Ghosh Sudakshina S Dweik Raed A RA Golish Joseph J Kinter Michael M Stuehr Dennis J DJ Erzurum Serpil C SC Aulak Kulwant S KS

American journal of respiratory and critical care medicine 20050609 5

<h4>Rationale</h4>A cellular prooxidant state promotes cells to neoplastic growth, in part because of modification of proteins and their functions. Reactive nitrogen species formed from nitric oxide (NO) or its metabolites, can lead to protein tyrosine nitration, which is elevated in lung cancer.<h4>Objective</h4>To determine the alteration in these NO derivatives and the role they may play in contributing to lung carcinogenesis.<h4>Methods</h4>We analyzed levels of NO, nitrite (NO2-), nitrate ( ...[more]

PMID: 15947282

Similar Datasets

Project description:BackgroundNitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer.MethodWe carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed.ResultsFifty studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89-4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84-1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA = 83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA = 95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04-0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy.ConclusionFeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

Dataset Information

Abnormalities in nitric oxide and its derivatives in lung cancer.

Rationale

Objective

Methods

Measurements and main results

Conclusions

Publications

Abnormalities in nitric oxide and its derivatives in lung cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets